The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies
- PMID: 28304217
- PMCID: PMC5891690
- DOI: 10.1177/1352458517695468
The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies
Abstract
Teriflunomide is a once-daily oral immunomodulator approved for relapsing-remitting multiple sclerosis (MS). The objective of this post hoc analysis of the phase 3, pooled TEMSO (NCT00134563) and TOWER (NCT00751881) dataset is to evaluate the effect of teriflunomide treatment on annualised relapse rate and disability worsening across patient subgroups defined according to prior disease-modifying therapy exposure. This analysis provides further supportive evidence for a consistent effect of teriflunomide across a broad range of patients with relapsing MS, including patients who have used and discontinued other disease-modifying therapies.
Keywords: ARR and disability worsening; RRMS; TEMSO; TOWER; Teriflunomide; disease-modifying treatment.
Conflict of interest statement
Figures
![Figure 1.](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/82a4/5891690/1a8a84d8dec4/10.1177_1352458517695468-fig1.gif)
Similar articles
-
Prior treatment status: impact on the efficacy and safety of teriflunomide in multiple sclerosis.BMC Neurol. 2020 Oct 6;20(1):364. doi: 10.1186/s12883-020-01937-4. BMC Neurol. 2020. PMID: 33023488 Free PMC article. Clinical Trial.
-
Teriflunomide: A Review in Relapsing-Remitting Multiple Sclerosis.Drugs. 2019 Jun;79(8):875-886. doi: 10.1007/s40265-019-01135-8. Drugs. 2019. PMID: 31098896 Review.
-
Matching-adjusted comparisons demonstrate better clinical outcomes in patients with relapsing multiple sclerosis treated with peginterferon beta-1a than with teriflunomide.Mult Scler Relat Disord. 2020 May;40:101954. doi: 10.1016/j.msard.2020.101954. Epub 2020 Jan 17. Mult Scler Relat Disord. 2020. PMID: 32078948 Clinical Trial.
-
Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis.Mult Scler Relat Disord. 2016 Nov;10:204-212. doi: 10.1016/j.msard.2016.10.010. Epub 2016 Nov 3. Mult Scler Relat Disord. 2016. PMID: 27919491 Clinical Trial.
-
Teriflunomide: a once-daily oral medication for the treatment of relapsing forms of multiple sclerosis.Clin Ther. 2015 Oct 1;37(10):2366-80. doi: 10.1016/j.clinthera.2015.08.003. Epub 2015 Sep 11. Clin Ther. 2015. PMID: 26365096 Review.
Cited by
-
Drug repurposing for neuroregeneration in multiple sclerosis.Neural Regen Res. 2018 Aug;13(8):1366-1367. doi: 10.4103/1673-5374.235242. Neural Regen Res. 2018. PMID: 30106047 Free PMC article. No abstract available.
-
Prior treatment status: impact on the efficacy and safety of teriflunomide in multiple sclerosis.BMC Neurol. 2020 Oct 6;20(1):364. doi: 10.1186/s12883-020-01937-4. BMC Neurol. 2020. PMID: 33023488 Free PMC article. Clinical Trial.
-
Teriflunomide as a therapeutic means for myelin repair.J Neuroinflammation. 2023 Jan 7;20(1):7. doi: 10.1186/s12974-022-02686-6. J Neuroinflammation. 2023. PMID: 36611185 Free PMC article.
-
Molecular Interventions towards Multiple Sclerosis Treatment.Brain Sci. 2020 May 15;10(5):299. doi: 10.3390/brainsci10050299. Brain Sci. 2020. PMID: 32429225 Free PMC article. Review.
-
Teriflunomide: A Review in Relapsing-Remitting Multiple Sclerosis.Drugs. 2019 Jun;79(8):875-886. doi: 10.1007/s40265-019-01135-8. Drugs. 2019. PMID: 31098896 Review.
References
-
- Gajofatto A, Bacchetti P, Grimes B, et al. Switching first-line disease-modifying therapy after failure: Impact on the course of relapsing-remitting multiple sclerosis. Mult Scler 2009; 15: 50–58. - PubMed
-
- Freedman MS, Selchen D, Arnold DL, et al. Treatment optimization in MS: Canadian MS Working Group updated recommendations. Can J Neurol Sci 2013; 40: 307–323. - PubMed
-
- O’Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011; 365: 1293–1303. - PubMed
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources